WO2001072335A3 - Methods for effecting neuroprotection using a potassium channel modulator - Google Patents

Methods for effecting neuroprotection using a potassium channel modulator Download PDF

Info

Publication number
WO2001072335A3
WO2001072335A3 PCT/CA2001/000391 CA0100391W WO0172335A3 WO 2001072335 A3 WO2001072335 A3 WO 2001072335A3 CA 0100391 W CA0100391 W CA 0100391W WO 0172335 A3 WO0172335 A3 WO 0172335A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
potassium channel
channel modulator
patient
excitable cells
Prior art date
Application number
PCT/CA2001/000391
Other languages
French (fr)
Other versions
WO2001072335A2 (en
Inventor
Alastair V Ferguson
Jaideep S Bains
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Priority to AU2001242184A priority Critical patent/AU2001242184A1/en
Priority to CA002403555A priority patent/CA2403555A1/en
Publication of WO2001072335A2 publication Critical patent/WO2001072335A2/en
Publication of WO2001072335A3 publication Critical patent/WO2001072335A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods for preventing damage to excitable cells following ischemic by administering to a patient who is undergoing or who has undergone an ischemic event an effective amount of a compound which increases a transient potassium (K+) conductance in the excitable cells of the patient. The present invention also provides a method for screening for compounds which increase a transient K+ current in the excitable cells of a patient.
PCT/CA2001/000391 2000-03-28 2001-03-27 Methods for effecting neuroprotection using a potassium channel modulator WO2001072335A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001242184A AU2001242184A1 (en) 2000-03-28 2001-03-27 Methods for effecting neuroprotection using a potassium channel modulator
CA002403555A CA2403555A1 (en) 2000-03-28 2001-03-27 Methods for effecting neuroprotection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19258500P 2000-03-28 2000-03-28
US60/192,585 2000-03-28

Publications (2)

Publication Number Publication Date
WO2001072335A2 WO2001072335A2 (en) 2001-10-04
WO2001072335A3 true WO2001072335A3 (en) 2002-08-01

Family

ID=22710287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000391 WO2001072335A2 (en) 2000-03-28 2001-03-27 Methods for effecting neuroprotection using a potassium channel modulator

Country Status (4)

Country Link
US (1) US20020022587A1 (en)
AU (1) AU2001242184A1 (en)
CA (1) CA2403555A1 (en)
WO (1) WO2001072335A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290731A1 (en) * 1999-11-26 2001-05-26 D. Jed Harrison Apparatus and method for trapping bead based reagents within microfluidic analysis system
US6432290B1 (en) 1999-11-26 2002-08-13 The Governors Of The University Of Alberta Apparatus and method for trapping bead based reagents within microfluidic analysis systems
US20030108664A1 (en) * 2001-10-05 2003-06-12 Kodas Toivo T. Methods and compositions for the formation of recessed electrical features on a substrate
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
US20030217923A1 (en) * 2002-05-24 2003-11-27 Harrison D. Jed Apparatus and method for trapping bead based reagents within microfluidic analysis systems
WO2004061085A2 (en) 2002-12-30 2004-07-22 The Regents Of The University Of California Methods and apparatus for pathogen detection and analysis
US7799553B2 (en) 2004-06-01 2010-09-21 The Regents Of The University Of California Microfabricated integrated DNA analysis system
ATE493973T1 (en) 2004-06-04 2011-01-15 Teva Pharma PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
EP1794581A2 (en) * 2004-09-15 2007-06-13 Microchip Biotechnologies, Inc. Microfluidic devices
US7749365B2 (en) * 2006-02-01 2010-07-06 IntegenX, Inc. Optimized sample injection structures in microfluidic separations
WO2008030631A2 (en) * 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Microfluidic devices
US7766033B2 (en) * 2006-03-22 2010-08-03 The Regents Of The University Of California Multiplexed latching valves for microfluidic devices and processors
US8841116B2 (en) * 2006-10-25 2014-09-23 The Regents Of The University Of California Inline-injection microdevice and microfabricated integrated DNA analysis system using same
WO2008115626A2 (en) * 2007-02-05 2008-09-25 Microchip Biotechnologies, Inc. Microfluidic and nanofluidic devices, systems, and applications
US8454906B2 (en) * 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
WO2009108260A2 (en) * 2008-01-22 2009-09-03 Microchip Biotechnologies, Inc. Universal sample preparation system and use in an integrated analysis system
KR20110111449A (en) 2008-12-31 2011-10-11 인터젠엑스 인크. Instrument with microfluidic chip
CN102459565A (en) 2009-06-02 2012-05-16 尹特根埃克斯有限公司 Fluidic devices with diaphragm valves
JP2012529268A (en) 2009-06-05 2012-11-22 インテジェンクス，インコーポレイテッド Use of universal sample preparation system and integrated analysis system
US8584703B2 (en) 2009-12-01 2013-11-19 Integenx Inc. Device with diaphragm valve
US8512538B2 (en) 2010-05-28 2013-08-20 Integenx Inc. Capillary electrophoresis device
WO2012024657A1 (en) 2010-08-20 2012-02-23 IntegenX, Inc. Microfluidic devices with mechanically-sealed diaphragm valves
WO2012024658A2 (en) 2010-08-20 2012-02-23 IntegenX, Inc. Integrated analysis system
TWI592156B (en) * 2011-10-04 2017-07-21 艾可達醫療公司 Methods for treating a stroke-related sensorimotor impairment using aminopyridines
US20150136604A1 (en) 2011-10-21 2015-05-21 Integenx Inc. Sample preparation, processing and analysis systems
US10865440B2 (en) 2011-10-21 2020-12-15 IntegenX, Inc. Sample preparation, processing and analysis systems
CN105873681B (en) 2013-11-18 2019-10-11 尹特根埃克斯有限公司 Cartridge and instrument for sample analysis
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
EP3552690A1 (en) 2014-10-22 2019-10-16 IntegenX Inc. Systems and methods for sample preparation, processing and analysis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAI D ET AL: "ANG II AT1 RECEPTORS INDUCE DEPOLARIZATION AND INWARD CURRENT IN RAT MEDIAN PREOPTIC NEURONS IN VITRO", AMERICAN JOURNAL OF PHYSIOLOGY: REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 275, no. 2, PART 2, August 1998 (1998-08-01), pages R632 - R639, XP001037989, ISSN: 0363-6119 *
BAINS J S ET AL: "HYPERPOLARIZING AFTER-POTENTIALS REGULATE GENERATION OF LONG- DURATION PLATEAU DEPOLARIZATIONS IN RAT PARAVENTRICULAR NUCLEUS NEURONS", EUROPEAN JOURNAL OF NEUROSCIENCE, OXFORD UNIVERSITY PRESS, GB, vol. 10, no. 4, April 1998 (1998-04-01), pages 1412 - 1421, XP001038198, ISSN: 0953-816X *
BAINS J S ET AL: "REDUCED NMDA RECEPTOR SENSITIVITY MAY UNDERLIE THE RESISTANCE OF SUBPOPULATIONS OF PVN NEURONS TO EXCITOTOXICITY", NEUROREPORT, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 8, no. 9/10, 7 July 1997 (1997-07-07), pages 2101 - 2105, XP001038196, ISSN: 0959-4965 *
GEORGIEV V ET AL: "Participation of angiotensin receptors in acute hypoxia in mice. I. Effects of angiotensin peptide receptor ligands saralasin and sarmesin.", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 21, no. 6, July 1999 (1999-07-01), pages 415 - 419, XP001027117, ISSN: 0379-0355 *
GEORGIEV V ET AL: "Participation of angiotensin receptors in acute hypoxia in mice. II. Effects of angiotensin II nonpeptide receptor ligands losartan (DuP-753) and PD-123319.", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 21, no. 7, 1999, pages 463 - 466, XP001026587, ISSN: 0379-0355 *
LI Y-W ET AL: "ANGIOTENSIN II DECREASES A RESTING K+ CONDUCTANCE IN RAT BULBOSPINAL NEURONS OF THE C1 AREA", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 78, no. 2, 1996, pages 274 - 282, XP001038671, ISSN: 0009-7330 *
NICHOLLS D ET AL: "THE RELEASE AND UPTAKE OF EXCITATORY AMINO ACIDS", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 11, no. 11, 1990, pages 462 - 468, XP002188730, ISSN: 0165-6147 *

Also Published As

Publication number Publication date
US20020022587A1 (en) 2002-02-21
CA2403555A1 (en) 2001-10-04
AU2001242184A1 (en) 2001-10-08
WO2001072335A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2001072335A3 (en) Methods for effecting neuroprotection using a potassium channel modulator
DE69927507D1 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF ABNORMAL CELL REPRODUCTION
AU4441096A (en) Preparation and stabilisation of cells
YU66204A (en) Cycloalkyl inhibitors of potassium channel function
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
DE69433010D1 (en) METHOD FOR PRESENTING OLIGONUCLEOTIDES
MX9606546A (en) INHIBITORS OF INTERLEUKIN-1'beta' CONVERTING ENZYME.
PL331802A1 (en) Substituted cyclic amines as metaloprotease inhibitors
EP0931788A3 (en) Metalloprotease inhibitors
NO952077L (en) A composition consisting of a dendrimer and an active substance occluded therein
AU2251901A (en) Methods and compounds for inhibiting MRP1
AU6365799A (en) High purity gallium for preparation of compound semiconductor, and method and apparatus for purifying the same
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
NO994364L (en) Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at C-terminal end
ATE502647T1 (en) PREPARATIONS CONTAINING SINCALIDE
MXPA01003501A (en) Method to mitigate plant stress.
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
WO2004008286A3 (en) Arrangements and methods for treating a subject
PL307629A1 (en) 1 alpha-fluoro-25-hydroxyl-16-ene-23-yne-cholecalcferol, method of obtaining same and pharmaceutical compositions containing it
EP1215599A4 (en) Method for evaluating distribution value of right and device used therefor
TR200003202T1 (en) Cyclopentanone dihydropyridine compounds useful as potassium channel openers
WO2002000624A3 (en) Methods and compounds for inhibiting mrp1
GR3024660T3 (en) Distillative method of recovering glycols from used antifreeze agents
WO2003006645A3 (en) Method and composition for inhibiting heparanase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2403555

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP